Open Access
Issue
4open
Volume 4, 2021
Article Number 3
Number of page(s) 13
Section Life Sciences - Medicine
DOI https://doi.org/10.1051/fopen/2021003
Published online 21 July 2021
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021), Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71, 3, 209–249. https://doi.org/10.3322/caac.21660. [Google Scholar]
  • Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA (2020), International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer 147, 2, 317–330. https://doi.org/10.1002/ijc.32723. [Google Scholar]
  • Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK (2018), Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379, 1, 54–63. https://doi.org/10.1056/NEJMoa1717002. [Google Scholar]
  • Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH-2 study investigators (2019), Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20, 2, 282–296. https://doi.org/10.1016/S1470-2045(18)30937-9. [Google Scholar]
  • Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018), Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 10126, 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1. [Google Scholar]
  • Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators (2020), Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382, 20, 1894–1905. https://doi.org/10.1056/NEJMoa1915745. [Google Scholar]
  • Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Park SR, Ryu MH, Ryoo BY, Choi J (2020), Effectiveness and safety of nivolumab in Child-Pugh B patients with hepatocellular carcinoma: a real-world cohort study. Cancers (Basel) 12, 7, 1968. https://doi.org/10.3390/cancers12071968. [Google Scholar]
  • Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B (2009), Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res 28, 1, 51. https://doi.org/10.1186/1756-9966-28-51. [Google Scholar]
  • Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B (2011), Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer 105, 5, 640–648. https://doi.org/10.1038/bjc.2011.292. [Google Scholar]
  • Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D’Agostino RB Jr, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC (2019), Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine 44, 209–224. https://doi.org/10.1016/j.ebiom.2019.05.034. [Google Scholar]
  • Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N (2012), Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer 106, 2, 307–313. https://doi.org/10.1038/bjc.2011.523. [Google Scholar]
  • Pasche B (2018), How tumor-specific modulation frequencies were discovered. Cancer Lett 44, 37, 24–29. https://www.therabionic.com/wp-content/uploads/2018/10/How-tumor-specific-modulation-frequencies-were-discovered-October-2018.pdf. [Google Scholar]
  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000), New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 3, 205–216. https://doi.org/10.1093/jnci/92.3.205. [Google Scholar]
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009), New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 2, 228–247. https://doi.org/10.1016/j.ejca.2008.10.026. [Google Scholar]
  • Llovet JM, Montal R, Villanueva A (2019), Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol 70, 6, 1262–1277. https://doi.org/10.1016/j.jhep.2019.01.028. [Google Scholar]
  • Basch E, Rogak LJ, Dueck AC (2016), Methods for implementing and reporting Patient-reported Outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther 38, 4, 821–830. https://doi.org/10.1016/j.clinthera.2016.03.011. [Google Scholar]
  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008), Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 4, 378–390. https://doi.org/10.1056/NEJMoa0708857. [Google Scholar]
  • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009), Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10, 1, 25–34. https://doi.org/10.1016/S1470-2045(08)70285-7. [Google Scholar]
  • Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE Investigators (2017), Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 10064, 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9. [Google Scholar]
  • McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E (2018), Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 105, 2018, 1–9. https://doi.org/10.1016/j.ejca.2018.09.031. [Google Scholar]
  • Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S (2011), Safety and efficacy of sorafenib in patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 4, 2, 40–44. [Google Scholar]
  • Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006), Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24, 26, 4293–4300. https://doi.org/10.1200/JCO.2005.01.3441. [Google Scholar]
  • Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016), The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24, 8, 3669–3676. https://doi.org/10.1007/s00520-016-3297-9. [Google Scholar]
  • Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG Jr, Kish JK (2020), Use of real-world evidence to support FDA approval of oncology drugs. Value Health 23, 10, 1358–1365. https://doi.org/10.1016/j.jval.2020.06.006. [Google Scholar]